What You Need to Know Ahead of Eli Lilly Earnings

Key Metric: Mounjaro, Zepbound Sales

Demand for nan weight-loss narcotics has boosted nan gross and shares of Eli Lilly on pinch Ozempic and Wegovy-maker Novo Nordisk (NVO) complete nan past year, arsenic nan companies person accrued accumulation capacity to meet demand.

In its first-quarter report, Eli Lilly lifted its gross and profit projections for nan afloat twelvemonth owed to beardown income for nan weight-loss drugs.

JPMorgan analysts wrote Monday that Eli Lilly remains 1 of their "core holdings" successful nan pharmaceutical space, particularly arsenic nan banal has fallen successful caller weeks amid a market-wide rotation out of immoderate of nan largest stocks connected nan market..

Business Spotlight: Increasing Weight-Loss Competition

Eli Lilly and Novo Nordisk's power successful nan weight-loss abstraction could beryllium challenged successful nan coming quarters arsenic narcotics from competitors for illustration Viking Therapeutics (VKTX) and Swiss drugmaker Roche person showed affirmative results successful early trials. Telehealth institution Hims & Hers Health (HIMS) announced its own weight-loss offerings successful nan quarter, perchance astatine a little costs than celebrated narcotics for illustration Ozempic and Mounjaro.

JPMorgan analysts said they judge Eli Lilly and Novo Nordisk are apt to "remain dominant" successful nan weight nonaccomplishment abstraction going guardant contempt accrued competition. They proceed to spot "significant upside" to Mounjaro and Zepbound sales.

Eli Lilly shares were up 1.8% Wednesday to supra $804, much than 37% supra wherever they started nan year, but down from grounds levels seen earlier this month.